glp-1 drugs what is it Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity Understanding GLP Drugs: What They
Description
Robert et al., 2015)
Zhang Y, Zhang Q, Bai Y, Zheng H, Ji L, Zhu X, Sun W, Liu X, Zhang S, Li Y, Lu B (2023) Glycogen synthesis kinase-3beta involves in the analgesic effect of liraglutide on diabetic neuropathic pain
The most frequently reported side effects were mild to moderate nausea and diarrhea
Recent final draft guidance from NICE (2026a) has recommended semaglutide up to a dose of 2.4 mg subcutaneously once weekly for people without diabetes and: with pre-existing CVD (previous MI, stroke or peripheral vascular disease) and a BMI of 27 kg/m 2 for CV protection (to reduce CV death, non-fatal MI, non-fatal stroke)
Weight loss and hormonal balance can indirectly help fertility
Novo Nordisk files for US FDA regulatory approval of once-weekly semaglutide 2.4 mg for weight management
